Endothelial dysfunction occurs prior to clinical evidence of polycystic kidney disease

American Journal of Nephrology

Volumn 38, Issue 3, 2013, Pages 233-240

  Peterson, Karen M ^a   Franchi, Federico ^a   Loeffler, Darrel L ^a   Psaltis, Peter J ^a   Harris, Peter C ^a   Lerman, Lilach O ^a   Lerman, Amir ^a   Rodriguez Porcel, Martin ^a  

^a MAYO CLINIC   (United States)

Author keywords

Acetylcholine; Autosomal inheritance; Cardiovascular disease; Endothelial dysfunction; Polycystic kidney disease

Indexed keywords

ARGININE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ACETYL LOW DENSITY LIPOPROTEIN; BRADYKININ; NITRIC OXIDE; VON WILLEBRAND FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL REACTIVITY; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CREATININE CLEARANCE; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; FEMALE; HEMODYNAMICS; KIDNEY FUNCTION; KIDNEY PERFUSION; KIDNEY POLYCYSTIC DISEASE; MEAN ARTERIAL PRESSURE; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SYSTOLIC BLOOD PRESSURE; VASODILATATION; ANGIOGENESIS; CELL DEATH; KIDNEY BLOOD FLOW;

ACETYLCHOLINE; ANIMALS; AORTA; CELL PROLIFERATION; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; FEMALE; HEMODYNAMICS; KIDNEY; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; OXIDATIVE STRESS; POLYCYSTIC KIDNEY DISEASES; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS; VASCULAR DISEASES;

EID: 84885032006     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000354236     Document Type: Article

References (20)

1. Harris PC, Torres VE: Polycystic kidney disease. Annu Rev Med 2009; 60: 321-337.
2. Torres VE: New insights into polycystic kidney disease and its treatment. Curr Opin Nephrol Hypertens 1998; 7: 159-169.
3. Torres VE, Harris PC: Polycystic kidney disease: genes, proteins, animal models, disease mechanisms and therapeutic opportunities. J Intern Med 2007; 261: 17-31.
4. Torres VE, Harris PC: Autosomal dominant polycystic kidney disease: the last 3 years. Kidney Int 2009; 76: 149-168.
5. Wang D, Iversen J, Strandgaard S: Endothelium-dependent relaxation of small resistance vessels is impaired in patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2000; 11: 1371-1376.
6. Wang D, Iversen J, Wilcox CS, Strandgaard S: Endothelial dysfunction and reduced nitric oxide in resistance arteries in autosomaldominant polycystic kidney disease. Kidney Int 2003; 64: 1381-1388.
7. Lavi S, Bae JH, Rihal CS, Prasad A, Barsness GW, Lennon RJ, Holmes DR Jr, Lerman A: Segmental coronary endothelial dysfunction in patients with minimal atherosclerosis is associated with necrotic core plaques. Heart 2009; 95: 1525-1530.
8. Lerman A, Holmes DR Jr, Bell MR, Garratt KN, Nishimura RA, Burnett JC Jr: Endothelin in coronary endothelial dysfunction and early atherosclerosis in humans. Circulation 1995; 92: 2426-2431.
9. Lager DJ, Qian Q, Bengal RJ, Ishibashi M, Torres VE: The PCK rat: a new model that resembles human autosomal dominant polycystic kidney and liver disease. Kidney Int 2001; 59: 126-136.
10. Stroope A, Radtke B, Huang B, Masyuk T, Torres V, Ritman E, LaRusso N: Hepato-renal pathology in pkd2ws25/-mice, an animal model of autosomal dominant polycystic kidney disease. Am J Pathol 2010; 176: 1282-1291.
11. Xu R, Franchi F, Miller B, Crane JA, Peterson KM, Psaltis PJ, Harris PC, Lerman LO, Rodriguez-Porcel M: Polycystic kidneys have decreased vascular density: a micro-CT study. Microcirculation 2013; 20: 183-189.
12. Rodriguez-Porcel M, Lerman LO, Holmes DR, Richardson D, Napoli C, Lerman A: Chronic antioxidant supplementation attenuates nuclear factor-?B activation and preserves endothelial function in hypercholesterolemic pigs. Cardiovasc Res 2002; 53: 1010-1018.
13. Ward CJ, Hogan MC, Rossetti S, Walker D, Sneddon T, Wang X, Kubly V, Cunningham JM, Bacallao R, Ishibashi M, Milliner DS, Torres VE, Harris PC: The gene mutated in autosomal recessive polycystic kidney disease encodes a large, receptor-like protein. Nat Ge net 2002; 30: 259-269.
14. Nagao S, Yamaguchi T: PPAR-gamma agonists in polycystic kidney disease with frequent development of cardiovascular disorders. Curr Mol Pharmacol 2012; 5: 292-300.
15. Wang D, Strandgaard S, Borresen ML, Luo Z, Connors SG, Yan Q, Wilcox CS: Asymmetric dimethylarginine and lipid peroxidation products in early autosomal dominant polycystic kidney disease. Am J Kidney Dis 2008; 51: 184-191.
16. Tao Y, Kim J, Faubel S, Wu JC, Falk SA, Schrier RW, Edelstein CL: Caspase inhibition reduces tubular apoptosis and proliferation and slows disease progression in polycystic kidney disease. Proc Natl Acad Sci USA 2005; 102: 6954-6959.
17. Lanoix J, D'Agati V, Szabolcs M, Trudel M: Dysregulation of cellular proliferation and apoptosis mediates human autosomal dominant polycystic kidney disease (ADPKD). Oncogene 1996; 13: 1153-1160.
18. Nauli SM, Kawanabe Y, Kaminski JJ, Pearce WJ, Ingber DE, Zhou J: Endothelial cilia are fluid shear sensors that regulate calcium signaling and nitric oxide production through polycystin-1. Circulation 2008; 117: 1161-1171.
19. Nauli SM, Jin X, Hierck BP: The mechanosensory role of primary cilia in vascular hypertension. Int J Vasc Med 2011; 2011: 376-281.
20. Thomas SR, Chen K, Keaney JF Jr: Oxidative stress and endothelial nitric oxide bioactivity. Antioxid Redox Signal 2003; 5: 181-194.